The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a huge mover today! About 514,621 shares traded hands. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 25.74% since April 5, 2016 and is uptrending. It has outperformed by 23.78% the S&P500.
The move comes after 6 months positive chart setup for the $433.47M company. It was reported on Nov, 8 by Barchart.com. We have $11.83 PT which if reached, will make NASDAQ:PGNX worth $446.47 million more.
Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on November, 14. They expect $0.52 earnings per share, up 471.43% or $0.66 from last year’s $-0.14 per share. PGNX’s profit will be $38.66M for 2.80 P/E if the $0.52 EPS becomes a reality. After $-0.08 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -750.00% EPS growth.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage
Out of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was upgraded by Jefferies to “Buy” on Friday, October 23. On Friday, August 7 the stock rating was maintained by Needham with “Buy”. Zacks downgraded Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Friday, August 7 to “Buy” rating. The rating was initiated by Aegis Capital on Thursday, October 27 with “Buy”. The firm has “Buy” rating given on Thursday, August 6 by Brean Capital.
According to Zacks Investment Research, “Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in 2016 Q2. Its down 0.09, from 0.85 in 2016Q1. The ratio dropped, as 25 funds sold all Progenics Pharmaceuticals, Inc. shares owned while 29 reduced positions. 12 funds bought stakes while 29 increased positions. They now own 58.35 million shares or 1.82% less from 59.43 million shares in 2016Q1.
Citigroup holds 7,658 shares or 0% of its portfolio. Vanguard Group has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Da Davidson has 1,000 shares for 0% of their US portfolio. Ladenburg Thalmann Fin Services Inc has 2,819 shares for 0% of their US portfolio. Moreover, Geode Cap Management Lc has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 457,275 shares. Tfs Ltd Co reported 60,575 shares or 0.05% of all its holdings. Swiss Bancorp has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). The New York-based Bnp Paribas Arbitrage has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Northern Tru accumulated 808,834 shares or 0% of the stock. Savings Bank Of New York Mellon holds 559,054 shares or 0% of its portfolio. Fisher Asset Management Lc has 0% invested in the company for 140,361 shares. Legal And General Gru Public Limited Com holds 0% or 12,790 shares in its portfolio. Phocas Corp accumulated 0.2% or 649,295 shares. Royal Financial Bank Of Canada, a Ontario – Canada-based fund reported 438 shares. Moreover, Ubs Asset Mgmt Americas has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 34,100 shares.
More news for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were recently published by: Fool.com, which released: “Why Progenics Pharmaceuticals, Inc. Shares Soared Today” on July 20, 2016. Globenewswire.com‘s article titled: “Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and …” and published on November 07, 2016 is yet another important article.
PGNX Company Profile
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.